查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887164

GLP-1受体激动剂市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032）

GLP-1 Receptor Agonist Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

GLP-1受体激动剂市场驱动因子

全球GLP-1受体激动剂市场正经历显着成长，这主要得益于糖尿病患者数量的增加、肥胖症盛行率的上升以及新一代GLP-1疗法的广泛应用。根据财富商业洞察（Fortune Business Insights）报告显示，该市场预计在2024年达到520.8亿美元，2025年增长至628.3亿美元，并在2032年达到1866.4亿美元，预测期内复合年增长率（CAGR）为16.8%。这一显着增长反映了全球治疗策略向晚期代谢疾病的转变，以及GLP-1药物因其血糖控制和体重减轻的双重益处而日益受到认可。

市场洞察与驱动因素

GLP-1受体激动剂模拟人类胰高血糖素样胜肽-1激素，可改善血糖控制、刺激胰岛素分泌并支持长期体重管理。其广泛应用主要受全球第二型糖尿病和肥胖症盛行率不断上升的推动。根据国际卫生组织统计，第2型糖尿病影响全球超过10%的成年人口，而肥胖症的盛行率仍以惊人的速度持续成长。 GLP-1药物可同时针对这两种疾病，从而推动了主要医疗保健市场需求的快速成长。

此外，诺和诺德、礼来、阿斯特捷利康和赛诺菲等主要製药公司正在不断开发GLP-1製剂，包括每週一次注射剂、高剂量製剂、口服GLP-1製剂和联合疗法。给药系统的创新以及对个人化治疗日益增长的关注，也进一步推动了市场的扩张。

依地区划分的市场亮点

2024年，北美在全球GLP-1受体激动剂市场占主导地位，市占率高达55.51%。该地区市场规模在2024年达到289.1亿美元，主要得益于肥胖和糖尿病的高发生率、先进的治疗基础设施以及强劲的药物研发投入。美国仍然是最大的贡献者，这主要得益于Ozempic、Wegovy、Munjaro和Libelsus等GLP-1药物的大规模生产扩张。

欧洲是第二大市场，这得益于主要製药厂商的存在、日益活跃的临床研究以及GLP-1疗法在糖尿病和肥胖症治疗中的应用不断增长。同时，亚太地区正经历快速增长，这主要归功于生活方式相关疾病的增加、医疗保健覆盖范围的扩大以及人们对现代代谢疗法的认识不断提高。中国和日本等国家正越来越多地将GLP-1药物引入临床实践。

市场趋势与限制因素

影响市场发展的关键趋势之一是将人工智慧和数位健康工具结合，以指导治疗方案的选择并优化患者疗效。基于人工智慧的平台正越来越多地被用于预测特定患者的最佳GLP-1疗法。

然而，市场成长仍受到限制。主要因素是GLP-1受体激动剂的高成本。在美国，平均每月治疗费用约为1000美元，这使得许多患者难以负担长期治疗。此外，仿製药供应受限以及全球需求激增导致的供应短缺也构成了额外的障碍。儘管面临这些挑战，但随着主要公司扩大生产能力，预计未来几年供应短缺的情况将有所缓解。

依细分市场分析

依药物类型划分，索玛鲁肽在2024年占最大的市场占有率，凭藉其高效性、每週一次的注射方案以及注射剂（Ozempic、Wegovy）和口服剂（Libelsus）两种剂型，保持了其领先地位。艾塞那肽和利拉鲁肽仍被广泛使用，而替泽帕肽等新型药物则呈现快速成长趋势。

依年龄组别划分，成人在2024年占了大部分使用量，这反映了全球成人发病型第二型糖尿病和肥胖症的高发生率。由于用于治疗青少年肥胖症的新药获批，GLP-1类药物在儿童中的使用量正在上升。

依给药途径划分，注射剂在2024年占主导地位，但由于患者更倾向于非注射疗法，口服製剂的需求正在迅速增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要适应症的流行情况（依主要国家/地区划分，2024 年）
  • 主要公司的产品线分析
  • 主要公司新产品发布状况
  • 主要产业趋势（併购、合作等）
  • 新冠疫情对市场的影响

第五章：全球GLP-1受体激动剂市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依药物分类
    • 索玛鲁肽
    • 艾塞那肽
    • 利西拉肽
    • 利拉鲁肽
    • 度拉鲁肽
    • 其他
  • 市场分析、洞察与预测 - 依给药途径
    • 口服
    • 注射
  • 市场分析、洞察与预测 - 依年龄组
    • 儿童
    • 成人
  • 市场分析、洞察与预测 - 依适应症
    • 糖尿病
    • 肥胖症
    • 其他
  • 市场分析、洞察与预测 - 依销售额管道
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美 GLP-1 受体激动剂市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲 GLP-1 受体激动剂市场分析、洞察与预测 (2019-2032)

  • 依国家/地区
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区 GLP-1 受体激动剂市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲 GLP-1 受体激动剂市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲 GLP-1 受体激动剂市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
    • 礼来公司
    • 赛诺菲
    • 诺和诺德
    • 阿斯特捷利康
    • 辉瑞公司
    • 格兰马克製药有限公司
    • 梯瓦製药工业股份有限公司
Product Code: FBI112827

Growth Factors of GLP-1 receptor agonist Market

The global GLP-1 receptor agonist market is witnessing exceptional expansion driven by rising cases of diabetes, increasing obesity prevalence, and strong uptake of next-generation GLP-1 therapies. According to the Fortune Business Insights report, the market was valued at USD 52.08 billion in 2024, is projected to rise to USD 62.83 billion in 2025, and is expected to reach USD 186.64 billion by 2032, registering a CAGR of 16.8% over the forecast period. This significant acceleration reflects the global shift toward advanced metabolic disorder treatments and the growing acceptance of GLP-1 drugs for their dual benefits-blood glucose control and weight reduction.

Market Insights and Drivers

GLP-1 receptor agonists mimic the human glucagon-like peptide-1 hormone, improving glycemic control, stimulating insulin secretion, and supporting long-term weight management. Their widespread adoption stems from increasing global prevalence of type 2 diabetes and obesity. As per international health bodies, type 2 diabetes affects over 10% of the global adult population, and obesity continues to grow at alarming rates. Because GLP-1 drugs target both conditions simultaneously, their demand has surged sharply across major healthcare markets.

In addition, major pharmaceutical players such as Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, and Sanofi continue to advance GLP-1 formulations, including once-weekly injectables, high-dose variations, oral GLP-1 options, and combination therapies. Innovations in delivery systems and the growing emphasis on personalized therapy are further supporting market expansion.

Regional Market Highlights

North America dominated the global GLP-1 receptor agonist market in 2024, accounting for 55.51% of total market share. The region's market value stood at USD 28.91 billion in 2024, driven by high obesity and diabetes rates, advanced treatment infrastructure, and strong pharmaceutical R&D investments. The United States remains the largest contributor, strengthened by large-scale manufacturing expansions for GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Rybelsus.

Europe represents the second-largest market, supported by the presence of leading pharmaceutical manufacturers, rising clinical research activities, and increasing adoption of GLP-1 therapies for both diabetes and obesity. Meanwhile, Asia Pacific is experiencing rapid growth due to rising lifestyle-related diseases, expanding healthcare access, and growing awareness of modern metabolic therapies. Countries such as China and Japan are increasingly integrating GLP-1 drugs into clinical practice.

Market Trends and Restraints

A major trend shaping the market is the integration of AI and digital health tools that guide treatment selection and optimize patient outcomes. AI-based platforms are increasingly being used to predict which GLP-1 therapy will deliver the best efficacy for specific patient profiles.

However, market growth faces restraints, primarily the high cost of GLP-1 receptor agonists. Monthly treatment costs in the U.S. average around USD 1,000, making long-term therapy challenging for many patients. The limited availability of generics and supply shortages-due to overwhelming global demand-pose additional barriers. Despite these challenges, manufacturing expansions by leading companies are expected to reduce shortages in the coming years.

Segmentation Insights

By drug type, semaglutide held the largest share in 2024 and continues to dominate due to its strong efficacy, once-weekly injection schedule, and availability in both injectable (Ozempic, Wegovy) and oral (Rybelsus) forms. Exenatide and liraglutide also remain widely used, while newer agents such as tirzepatide are seeing rapid growth.

By age group, adults accounted for the majority of usage in 2024, reflecting the high global incidence of adult-onset type 2 diabetes and obesity. Pediatric use of GLP-1 drugs is increasing due to new approvals for adolescent obesity treatment.

By route of administration, parenteral GLP-1 agonists dominated in 2024, though oral formulations are growing quickly due to patient preference for non-injectable therapies.

Conclusion

The GLP-1 receptor agonist market is set for strong long-term expansion, rising from USD 52.08 billion in 2024 to USD 186.64 billion by 2032. As obesity and diabetes rates surge globally, and as GLP-1 therapies gain broader approval for multiple indications, the demand for advanced metabolic treatments will continue to accelerate. The presence of established players and active product pipelines ensures that the market remains highly competitive and innovation-driven.

Segmentation By Drug

  • Semaglutide
  • Exenatide
  • Lixisenatide
  • Liraglutide
  • Dulaglutide
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adults

By Indication

  • Diabetes
  • Obesity
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Indications, By Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Semaglutide
    • 5.1.2. Exenatide
    • 5.1.3. Lixisenatide
    • 5.1.4. Liraglutide
    • 5.1.5. Dulaglutide
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Indication
    • 5.4.1. Diabetes
    • 5.4.2. Obesity
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Semaglutide
    • 6.1.2. Exenatide
    • 6.1.3. Lixisenatide
    • 6.1.4. Liraglutide
    • 6.1.5. Dulaglutide
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Indication
    • 6.4.1. Diabetes
    • 6.4.2. Obesity
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Semaglutide
    • 7.1.2. Exenatide
    • 7.1.3. Lixisenatide
    • 7.1.4. Liraglutide
    • 7.1.5. Dulaglutide
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Indication
    • 7.4.1. Diabetes
    • 7.4.2. Obesity
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Semaglutide
    • 8.1.2. Exenatide
    • 8.1.3. Lixisenatide
    • 8.1.4. Liraglutide
    • 8.1.5. Dulaglutide
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Indication
    • 8.4.1. Diabetes
    • 8.4.2. Obesity
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Semaglutide
    • 9.1.2. Exenatide
    • 9.1.3. Lixisenatide
    • 9.1.4. Liraglutide
    • 9.1.5. Dulaglutide
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Indication
    • 9.4.1. Diabetes
    • 9.4.2. Obesity
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Semaglutide
    • 10.1.2. Exenatide
    • 10.1.3. Lixisenatide
    • 10.1.4. Liraglutide
    • 10.1.5. Dulaglutide
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Indication
    • 10.4.1. Diabetes
    • 10.4.2. Obesity
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Eli Lilly and Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Novo Nordisk A/S
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AstraZeneca
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Glenmark Pharmaceuticals Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Teva Pharmaceutical Industries Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 2: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 4: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 5: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 8: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 10: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 11: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 14: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 16: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 17: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 19: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 20: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 21: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 22: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 23: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 26: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 27: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 28: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 29: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 32: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 33: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 34: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 35: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global GLP-1 Receptor Agonists Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024 & 2032
  • Figure 3: Global GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 5: Global GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024 & 2032
  • Figure 6: Global GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global GLP-1 Receptor Agonists Market Value (USD billion), by Region, 2024 & 2032
  • Figure 8: North America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 9: North America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 10: North America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 11: North America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 12: North America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 13: North America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 14: North America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 15: North America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 16: North America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America GLP-1 Receptor Agonists Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America GLP-1 Receptor Agonists Market Value Share (%), By Country, 2024
  • Figure 20: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 21: Europe GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 22: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 23: Europe GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 24: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 25: Europe GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 26: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 27: Europe GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 28: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 33: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 34: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 35: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 36: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion),by Age Group, 2024 & 2032
  • Figure 37: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 38: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 39: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 40: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 45: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 46: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 47: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 48: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 49: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 50: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 51: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 52: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 57: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 58: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 59: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 60: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 61: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 62: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 63: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 64: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global GLP-1 Receptor Agonists Market Share (%), By Company, 2024